Expression of the hepatitis B virus S protein results in the formation of a lipoprotein particle, the hepatitis B surface antigen (HBsAg). Such particles, produced in Saccharomyces cerevisiae, bind to the cell surface of monocytes through interaction with the lipopolysaccharide binding protein and the lipopolysaccharide receptor, CD14. This attachment is suggested to depend on the presence of charged phospholipids in the particles. In addition, such particles interfere with the lipopolysaccharide and interleukin-2-induced activation of monocytes. In the present study, it is reported that of three Saccharomyces cerevisiae-derived HBsAg preparations, two have a reduced capacity to bind to monocytes. A correlation with a reduced potential to inhibit the lipopolysaccharide-induced activation of monocytes and an increased potential to stimulate HBsAg-specific T-cell proliferation is observed. Surprisingly, differences in phospholipid content that might explain these observations, were not detected.
INTRODUCTION
Hepatitis B virus (HBV)-infected hepatocytes produce and secrete noninfectious particles, hepatitis B surface antigen (HBsAg). HBsAg consists mainly of spherical particles of 22-nm diameter and a small number of filamentous particles. These particles can accumulate to several 100 mg/ml in the circulation. The spherical particles contain viral-encoded membrane proteins and approximately 30% (by weight) of host cell-derived lipids. The S protein accounts for more than 90% of the protein contained in HBsAg. The L and M proteins form the remainder. These three proteins share 226 Cterminal amino acids. Both glycosylated and nonglycosylated forms of these viral membrane proteins are present in the particles [Seeger and Mason, 2000] . In 1981, a plasma-derived HBsAg vaccine was licensed in the United States. Plasma-derived HBsAg in the vaccine was soon replaced by recombinant HBsAg, produced in Saccharomyces cerevisiae. More recently, HBsAg produced in other yeasts (Hansenula polymorpha and Pichia pastoris) and mammalian cells is also being used. In contrast to the plasma and mammalian cellderived HBsAg, the different yeast-derived HBsAg particles contain only the nonglycosylated S-protein. Despite these differences in protein content and protein modifications, it is generally accepted that, both structurally and antigenically, the yeast-derived HBsAg closely resembles the natural and mammalian cellderived HBsAg.
Recently, it was shown that S. cerevisiae-expressed HBsAg (rHBsAg) suppressed the lipopolysaccharide (LPS) and interleukin-2 (IL-2)-induced production of proinflammatory cytokines, while upregulating the LPS-induced expression of the anti-inflammatory IL-10 by human monocytes [Vanlandschoot et al., 2002a,c] . Moreover, the preferential binding of rHBsAg to the monocytes of peripheral blood mononuclear cells (PBMCs) was observed [Vanlandschoot et al., 2002a] . The LPS receptor (CD14) was shown to be necessary for the attachment of rHBsAg to occur. A serum protein that enhanced the binding of rHBsAg to monocytes was identified as the lipopolysaccharide binding protein (LBP) [Vanlandschoot et al., 2002b] . Surprisingly, it was found that HBsAg, purified from plasma (pHBsAg), was not endowed with this property of binding in a LBPdependent manner to the surface of CD14-expressing cells. Experimental evidence was presented that charged phospholipids, not or no longer present in pHBsAg, were responsible for the interaction of rHBsAg with the (cellular) receptors [Vanlandschoot et al., 2002b] . Because of this difference between pHBsAg and rHBsAg, it was considered important to investigate whether HBsAg expressed in other yeasts or mammalian cells, might show differences in attachment to monocytes, and their capacity to interfere with the LPS-induced activation of monocytes. Several vaccine producers of HBsAg were contacted, but none was willing to supply HBsAg. The study was therefore limited to the use of three different lots of S. cerevisiaeexpressed rHBsAg, obtained form GlaxoSmithKline. Nevertheless, clear differences in binding, immune suppression, and T-cell immunogenicity were observed among these preparations.
MATERIALS AND METHODS rHBsAg
Three rHBsAg (subtype adw 2 ) preparations produced in S. cerevisiae were kindly provided by GlaxoSmithKline Biologicals (Rixensart, Belgium). DVP93/1 (1,000 mg/ ml) were produced and purified in 1993, and HEF002 (1,096 mg/ml) and HEP715 (1562 mg/ml) in 2000. These rHBsAg particles were dissolved in phosphate-buffered saline (PBS); no adjuvant or preservatives were added. The purity of the rHBsAg preparations was judged by high-performance liquid chromatography (HPLC) analysis, as well as by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie staining and is >98%. rHBsAg is composed of welldefined subviral particles, which contain only the nonglycosylated S protein. Similar preparations are used worldwide as human HBV vaccines after adsorption on to aluminum hydroxide.
rHBsAg (DVP93/1) was biotinylated using an enhanced chemiluminescence system (ECL) protein biotinylation module (RPN 2202, Amersham Pharmacia Biotech) as described by Vanlandschoot et al. [2002a] . Biotinylated rHBsAg (b-rHBsAg) was purified by gel filtration on a Sephadex G25 column using PBS; 1-ml fractions were collected, and the two b-rHBsAg peak fractions were pooled.
Enzyme-Linked Immunosorbent Assay
Maxisorb 96-well plates (Nunc, Roskilde, Denmark) were coated with rHBsAg or b-rHBsAg in PBS. The wells were blocked with 0.1% bovine serum albumin (BSA) in PBS, followed by three washings (PBS, 0.1% Triton X-100). HBsAg-specific monoclonal antibodies (MAb; 1 mg/ml) or horseradish peroxidase (HPO)-labeled streptavidin (SAPE) were added, and the plates were incubated for 1 hr at room temperature. Antibodies were detected with peroxidase-labeled goat-anti-human antibodies (Sigma). After three washings, 3.3 0 ,5,5 0 -tetramethylbenzidine (Sigma) was added. After 30 min, the reaction was stopped with 1 N H 2 SO 4 .
Antibodies
Human anti-HBsAg MAb F47B was a kind gift from Lia Sillekens (Centraal Laboratorium van de Bloedbank, Amsterdam). The human anti-a MAb, which recognizes the ''a'' determinant of HBsAg, was developed in the laboratory and biotinylated as described above for rHBsAg. For fluorescence-activated cell sorting (FACS) analysis, human antibodies were detected with rabbit anti-human F(ab 0 )2-FITC. Phycoerythrin-labeled streptavidin (Strep-PE) was obtained from Becton Dickinson.
LPS Binding Protein
LBP was expressed in Chinese hamster ovary (CHO) cells and was purified as described [Stelter et al., 1999] .
Cells
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats, using Ficoll-Hypaque centrifugation (density ¼ 1.077 g/ml; Nycomed Pharma, Oslo, Norway). Cells were stored in liquid nitrogen. THP-1 cells were grown in cRPMI (RPMI 1640-10% fetal cell serum [FCS] , 2 mM L-glutamine, 1 mM Napyruvate, 50 U/ml penicillin, 50 mg/ml streptomycin, 20 mM b-mercaptoethanol). To induce differentiation, 100 nM 1,25-dihydroxy vitamin D3 (Calbiochem) was added for 24 hr. CHO cells that express human CD14 and CHO cells transfected with the empty vector only [Jack et al., 1995; Stelter et al., 1997] were grown in MEM-a without nucleosides and ribonucleosides (Gibco-BRL) supplemented with 10% FCS, 2 mM Lglutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 100 nM (plasmid-transfected CHO cells), or 500 nM methotrexate (CHO cells that express CD14). Cultured cells were detached mechanically or with nonenzymatic cell dissociation buffer (Sigma), washed twice with 2% human AB serum (Bio-Whitaker) in Hank's balanced salt solution (HBSS; Gibco-BRL) (2% HS-HBSS), and stained as described below.
Staining of Cells
PBMCs were thawed and washed twice with 2% HS-HBSS; 10 6 cells were incubated with b-rHBsAg or rHBsAg in 200 ml HBSS for 90 min on ice. During this incubation, 2% HS or 0.5 mg/ml LBP was added as indicated. Human serum used in these binding assays was not heat-inactivated. After two washings with the same solution, cells were incubated with Strep-PE or HBsAgspecific antibodies, followed by FITC-labeled antibodies in 2% HS-HBSS for 1 hr on ice. After two washings, cells were resuspended in 1 ml 2% HS-HBSS or PBS, containing propidium iodide (PI). Cells were analyzed on a FACScan flow cytometer (Becton Dickinson). Dead cells, which incorporated PI, were gated out of analysis. At least 5,000 cells were counted per analysis. Fluorescence (530 nm for FITC and 580 nm for PE) was measured. Median fluorescence was determined in each case. The signals were acquired in a logarithmic mode for FL1 (FITC) and FL2 (PE). Threshold levels were set according to negative (Strep-PE only) and isotypic controls.
LPS Treatment of THP-1
In this study, 3.10 5 THP-1 cells were treated for 24 hr with 100 nM 1,25-dihydroxy vitamin D3. After washing, the cells were incubated in cRPMI with or without 10 ng/ml LPS (Escherichia coli 0111:B4, Sigma); 0, 1, 10, 25, or 50 mg/ml rHBsAg was added. Cell supernatants were collected after 4 hr and were tested for the presence of tumor necrosis factor-a (TNF-a).
Cytokine Determinations
The concentration of TNF-a in cell supernatant was determined using commercially available kits (Biosource) according to the manufacturer's instructions.
Lymphoproliferation Assay
Unfractionated PBMCs were suspended in RPMI 1640 medium supplemented with 25 mM Hepes, 50 U/ ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamin, 5 Â 10 À5 M b-mercaptoethanol, and 10% heat-inactivated human AB serum. PBMCs (2 Â 10 5 /well) from vaccinated or HBV-infected subjects were cultured for 6 days (378C in 5% CO 2 ) in 96-well round-bottomed microtiter plates containing rHBsAg particles at the concentrations indicated. All assays were carried out in triplicate, and 3 H-TdR (0.5 mCi/well, Amersham International, UK) was added 18 hr before termination. Cultures were harvested using an automated harvesting device and were assayed for 3 H-TdR incorporation by liquid scintillation counting in an LKB-Wallac 8100 Counter.
Phospholipid Extraction, Determination, and Quantification
Phospholipids were extracted according to a modified Bligh and Dyer method [Bligh and Dyer, 1959; Weerheim et al., 2002] . Phospholipids were determined and quantified by high-performance thin-layer chromatography (HPTLC) as described [Weerheim et al., 2002] .
RESULTS

Reduced Attachment of HEF002
and HEP715 to CD14 þ Cells
Two different methods were used to compare the binding capacities of the three rHBsAg preparations. The first assay was based on the antibody-mediated detection of rHBsAg bound to the surface of CHO cells that express CD14. However, this method requires that the different particles show a similar reactivity toward the antibody used. Using two different human MAbs (anti-a and F47B) the antigenic quality of the three preparations was shown to be similar (Fig. 1). More importantly, the results demonstrated that antibody F47B could be used to compare the binding of these rHBsAg preparations to the cell surface. The second assay was based on the capacity of nonbiotinylated rHBsAg to compete with the binding of biotinylated rHBsAg, derived from DVP93/1, to monocytes of PBMCs. Fig. 1 . Antigenic structure of DVP93/1, HEF002, and HEP715 is very similar. Enzyme-linked immunosorbent assay (ELISA) plates were coated with DVP93/1 (black circles), HEF002 (gray circles), and HEP715 (white circles). After blocking with bovine serum albumin (BSA), human monoclonal antibodies (MAbs) F47B (left) and anti-a (right) were allowed to bind to the particles. MAbs were detected with goat-anti human peroxidase-labeled antibodies.
CHO cells that expressed CD14 were incubated on ice with 2 mg/ml rHBsAg and 0.5 mg/ml LBP in HBSS. Bound rHBsAg was detected using antibody F47B and rabbit anti-human F(ab 0 )2-FITC. As shown in Figure 2 , attachment of HEF002 en HEP715 to the cell surface was five to six times lower as compared with the attachment of DVP93/1.
As shown in Figure 3 , the use of 5 mg/ml of nonbiotinylated DVP93/1 led to a reduction in binding of biotinylated DVP93/1 by more then 50%. A similar reduction required the use of $50 mg/ml HEF002 and HEP715. Taken together, these results demonstrated clearly the reduced capacity of these two rHBsAg preparations to bind to the cell surface of CD14-expressing cells.
HEF002 and HEP715 have a Reduced Capacity to Inhibit LPS-Induced Activation of THP-1 Cells
Previously, it was demonstrated that the coadministration of LPS and rHBsAg to monocytes or THP-1 cells led to a substantial inhibition in LPS-induced TNF-a secretion [Vanlandschoot et al., 2002a,c] . To determine whether the reduced binding of HEF002 and HEP715 to CD14 þ cells, correlated with a reduced inhibition of LPS-induced activation of monocytes, the THP-1 assay was used. Because THP-1 cells do not express CD14, cells were first treated with 100 nM 1,25-dihydroxy vitamin D3. Differentiated THP-1 cells were incubated with LPS in the presence of different concentrations of rHBsAg. Culture supernatant was collected after 4 hr of stimulation and tested for the presence of TNF-a. At this 4-hr time point, secretion has reached its maximum [Vanlandschoot et al., 2002c] . As shown in Figure 4 , a dose-dependent reduction of TNF-a secretion was observed when cells were stimulated with LPS in the presence of rHBsAg. However, using 50 mg/ml of rHBsAg, this reduction was twofold only for HEF002 and HEP715, while a 20-fold reduction was obtained using DVP93/1.
Enhanced Immune Recognition of HEP715 by PBMCs from High-Responder Hepatitis B Vaccinees
The observation of differences in binding among rHBsAg preparations, despite the fact that all were derived from the same yeast species, was rather unexpected. The observation that reduced binding could be correlated with reduced inhibition of LPS-induced activation of monocytes raised the idea that the immune-suppressive attachment to monocytes might influence the HBsAg-specific T-cell proliferation. If this assumption was correct, an enhanced proliferation was predicted when using the low binding rHBsAg preparations.
The proliferative response of HBsAg-specific T cells toward the three rHBsAg preparations was investi- gated, using unfractionated PBMCs from rHBsAg vaccinees (two high and two nonresponders) and two chronically infected patients. Increasing doses of rHBsAg were added to 2 Â 10 5 PBMCs. rHBsAg-specific proliferation was not observed for PBMCs derived from nonresponders vaccinees and chronically infected patients (Fig. 5) . PBMCs from all donors, except patient, proliferated when challenged with tetanus toxoid. This demonstrates that the lack of a response is specific for rHBsAg. HEP715 caused a significant higher proliferation (two-to fourfold) with PBMCs derived from the two different high responders, compared with the proliferation observed with DVP93/1.
DVP93/1, HEF002, and HEP715 Contain Similar Amounts of Phosphatidylinositol
Previously, it was reported that charged phospholipids determine whether binding of HBsAg to monocytes occur [Vanlandschoot et al., 2002b] . Because of the differences in attachment observed among DVP93/1, HEF002, and HEP715, it was expected to find differences in phospholipid content. However, as shown in Table I , the phospholipid content of DVP93/1, HEF002, and HEP715 was almost completely identical.
DISCUSSION
Since 1986, millions of doses of vaccines containing the S. cerevisiae-derived HBsAg have been administered. These vaccines are safe and immunogenic and have reduced the occurrence of hepatitis B infections in the targeted populations [Leroux-Roels et al., 2001] . HBsAg, purified from plasma, contains the three viral membrane proteins, which are partially glycosylated. Compared with the natural HBsAg, this yeast-derived HBsAg only contains the S protein, which is nonglycosylated. Another known difference, which attracted little attention, is the presence of phosphatidylinositol in the yeast-expressed HBsAg. This phospholipid is absent in the natural HBsAg particles. The phospholipids of S. cerevisiae-derived HBsAg have also been shown to contain much more smaller (C16/C18 ¼ 1.759) fatty acids compared with the natural HBsAg (C16/ C18 ¼ 0.484). In addition, S. cerevisiae-derived HBsAg contains more unsaturated fatty acids. As a result, the fluidity of S. cerevisiae-derived HBsAg lipid content is higher [Gavilanes et al., 1982; Van der Meeren et al., 1994] . The possible consequences of these differences in the lipid content and lipid structure have hardly been studied. Recent observations nevertheless demonstrate that such differences have unexpected consequences: S. cerevisiae-derived HBsAg, and not plasma-derived HBsAg, was shown to bind to monocytes through interaction with the LPS binding protein and CD14. Upon detergent removal of the lipids and reconstitution of the proteins with charged phospholipids like phosphatidylserine and phosphatidylglycerol, binding of natural HBsAg was observed [Vanlandschoot et al., 2002b] . Because phosphatidylinositol is the only charged phospholipid found in Saccharomyces-expressed HBsAg [ Van der Meeren et al., 1994 ; also data presented above], it was proposed that this lipid determines the interaction of rHBsAg with monocytes.
Initially, the purpose of the present study was to compare binding of HBsAg expressed in different yeast species (S. cerevisiae and H. polymorpha) and mammalian cells with monocytes and to investigate their immune-suppressive potential. The lipid content of HBsAg expressed in these hosts is indeed variable [Van der Meeren et al., 1994; Diminsky et al., 1997] . However, obtaining vaccine HBsAg for this research purpose was difficult. The study was therefore limited to the use of three different lots of S. cerevisiaeexpressed rHBsAg, obtained from GlaxoSmithKline. Surprisingly, the results of two different binding assays This enhanced T-cell recognition was observed with PBMCs from high-responder vaccinees. Taken together, these results suggest a possible correlation between the capacity of rHBsAg to bind to monocytes and the potential to interfere with the normal function of monocytes. The most likely explanation for the differences in binding observed among the three rHBsAg preparations was a difference in the phosphatidylinositol content of the particles. However, phospholipid content, and especially the amount of the charged phosphatidylinositol, was nearly identical. Although phospholipid content determines whether HBsAg particles can bind to monocytes, the possibility that a defined region of the S protein is involved in the interaction cannot be excluded [Vanlandschoot et al., 2002b] . Therefore, minor differences in folding among the three rHBsAg preparations might perhaps affect binding. Such rearrangements may be the consequence of the different properties of the yeast cells used for rHBsAg production, different purification methods, or storage conditions. However, all preparations were produced with the same stable transformed yeast strain, ruling out different host properties. DVP93/1 was stored for some time at À208C before putting it at À708C. HEF002 and HEP715 were stored at À708C. It is doubtful that this incubation at À208C is responsible for the high binding capacity of DVP93/1, because other recent rHBsAg preparations, all stored at À708C, showed either high or low binding (data not shown). The possibility that different purification conditions are an underlying determinant is currently under investigation.
Although what causes the differences in binding to CD14 positive cells is unclear, a correlation between binding capacity and immunosuppression is suggested. Whether the suppressive interaction of yeast-expressed HBsAg with monocytes affects the anti-HBs levels after immunization with pure rHBsAg, and whether this immunosuppressive effect is retained after adsorption of rHBsAg onto aluminum hydroxide, remains to be determined.
